A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Must have received: anti-PD-1 therapy

progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody

Must have received: anti-PD-L1 therapy

progressed within 12 weeks of last dose of anti-PD-1/PD-L1 blocking antibody

Must have received: BRAF inhibitor

received BRAF/MEK inhibitor in those with BRAF mutations

Must have received: MEK inhibitor

received BRAF/MEK inhibitor in those with BRAF mutations

Must have received: platinum-based chemotherapy

platinum doublet chemotherapy

Must have received: targeted therapy

progressed during/after ≥1 targeted therapy

Cannot have received: cell therapy involving prior conditioning chemotherapy

any form of cell therapy involving prior conditioning chemotherapy within the past 20 years